Risk stratification for progressive multifocal leukoencephalopathy in patients treated with natalizumab.
about
Cost-Effectiveness of Disease-Modifying Therapies in Multiple SclerosisMolecular biology, epidemiology, and pathogenesis of progressive multifocal leukoencephalopathy, the JC virus-induced demyelinating disease of the human brainOptimizing the initial choice and timing of therapy in relapsing-remitting multiple sclerosisStratification and monitoring of natalizumab-associated progressive multifocal leukoencephalopathy risk: recommendations from an expert groupBenefits versus risks of latest therapies in multiple sclerosis: a perspective reviewDiagnosis and Management of Multiple Sclerosis in ChildrenRisk of Biologic Therapy-Associated Progressive Multifocal Leukoencephalopathy: Use of the JC Virus Antibody Assay in the Treatment of Moderate-to-Severe Crohn's DiseaseCurrent and emerging therapies in multiple sclerosis: a systematic reviewWhat went wrong? The flawed concept of cerebrospinal venous insufficiency.Therapeutic interference with leukocyte recirculation in multiple sclerosis.Use of natalizumab in multiple sclerosis: current perspectives.Is the risk of progressive multifocal leukoencephalopathy the real reason for natalizumab discontinuation in patients with multiple sclerosis?Efficacy and side effects of natalizumab therapy in patients with multiple sclerosis.Natalizumab in Multiple Sclerosis: Long-Term Management.Immunological mechanism of action and clinical profile of disease-modifying treatments in multiple sclerosis.Anaplastic astrocytoma mimicking progressive multifocal leucoencephalopathy: a case report and review of the overlapping syndromesAdverse events in IBD: to stop or continue immune suppressant and biologic treatmentTreating multiple sclerosis with monoclonal antibodies: a 2013 update.Multiple sclerosis: overview of disease-modifying agentsRisk evaluation and monitoring in multiple sclerosis therapeutics.Immunological Markers for PML Prediction in MS Patients Treated with NatalizumabRisk acceptance in multiple sclerosis patients on natalizumab treatment.Treatment satisfaction, adherence and behavioral assessment in patients de-escalating from natalizumab to interferon βJC polyomavirus infection is strongly controlled by human leucocyte antigen class II variantsJC virus reactivation during prolonged natalizumab monotherapy for multiple sclerosis.Natalizumab in the pediatric MS population: results of the Italian registryClinical and radiologic rebound after discontinuation of natalizumab therapy in a highly active multiple sclerosis patient was not halted by dimethyl-fumarate: a case report.Natalizumab treatment reduces L-selectin (CD62L) in CD4+ T cells.Human polyomavirus JC replication and non-coding control region analysis in multiple sclerosis patients under natalizumab treatment.Multiple functional therapeutic effects of TnP: A small stable synthetic peptide derived from fish venom in a mouse model of multiple sclerosis.Natalizumab Discontinuation and Treatment Strategies in Patients with Multiple Sclerosis (MS): A Retrospective Study from Two Italian MS Centers.Disease-modifying therapy of pediatric multiple sclerosis.JC virus detection and JC virus-specific immunity in natalizumab-treated multiple sclerosis patients.Can we prevent or treat multiple sclerosis by individualised vitamin D supply?Epigallocatechin-3-gallate: a useful, effective and safe clinical approach for targeted prevention and individualised treatment of neurological diseases?Induction therapy for patients with multiple sclerosis: why? When? How?Risk-benefit considerations in the treatment of relapsing-remitting multiple sclerosis.Current and future therapies for multiple sclerosis.Human Polyomavirus JC monitoring and noncoding control region analysis in dynamic cohorts of individuals affected by immune-mediated diseases under treatment with biologics: an observational study.Prevalence of Anti-JC Virus Antibody in Multiple Sclerosis Patients in Kuwait.
P2860
Q22252598-635D2599-47B1-45C4-8005-9F10E73FDD8BQ24619923-60E6B685-E61A-41DA-A779-E3C95F872996Q26777686-7674B184-D0B0-4441-AAE8-9469D8899032Q26780412-30F34B6B-645D-4655-9C8B-102561B6BEA4Q26999417-43E2718A-788F-452B-9389-FC661A541D32Q28069571-004E1E3A-9BF7-446D-8E25-149682FF8D00Q28538974-42DD6C0D-59FF-4D49-B54B-6F26ED4C3203Q29010983-BA21752A-CCE7-4449-ADF7-1A55040786D6Q30454634-EBA5974D-1477-4AFE-B22E-1B6128BCF748Q30884219-4B972159-2FAC-4382-85AE-08016FF20DD6Q31114633-33412B72-CEA2-452E-8ED0-DC589DB8F087Q33562701-AA2026DF-DF3D-4FBB-8631-0D09F49F7A84Q33573208-76767F2E-5EBD-48A4-976D-20DD4DCE00E1Q33754882-0D12518C-A099-478A-A9BA-44ADD4B8E00DQ33755345-E08E97FC-D366-464C-8138-B0A56EA8B5F8Q33814485-0ED8F9D9-1F16-4B26-8ADA-6AC243A1C052Q34073191-3C2FBA8E-AD34-466D-9BCA-1B5BABCBB8E9Q34330211-14AE7BE9-5891-472C-9DC3-B6E78F64651AQ34342662-587D2F4B-77FC-402C-A275-C9158BF51A31Q34513188-882485A5-E807-421E-ADAF-397C1781BEB8Q34818048-FE4AEFD7-C12C-4929-A983-C70F3BEF2C18Q35067882-959AF250-6165-4EE1-8B01-4089535EDD11Q35103997-33ED6599-6939-45A4-8917-570E9971E390Q35157207-CFB2C917-ECAE-4CC6-AB0E-9CDBE4A0E9BBQ35586120-3FE99F51-999F-4EB9-B14B-2864F630B59AQ35788938-DC47807C-1BFC-4055-AC9A-3819EB21C264Q35862875-D7C65584-DF27-4EC9-A871-F6D539E893A9Q35939675-6F71B2AC-48AC-4041-AC80-1B66B55C93DEQ36234246-96FD32A2-B5B2-40E2-84C2-24B457EDC35FQ36290143-65B04107-9E5D-4C57-B404-3640656ACD98Q36389681-DDDE78FC-315B-4059-A774-96F3C600B641Q36568645-94C2E088-619D-402F-AD5F-13064EF0CA24Q36572168-19EA28F8-354E-4A79-9310-F38C89FDB3CCQ36588696-B2D26839-03D6-4458-9A19-7B4F2E43F809Q36648907-BA5539CB-1B3B-4E40-9F56-E57364BB1626Q36923587-C343B7DA-C14E-4199-BCE8-12B052D76462Q36975701-7EBA1E93-A961-4827-8796-130B55684246Q37287769-76EC2779-5E42-43F2-86F7-542C16C40776Q37361949-87AC7C50-1262-4E10-8949-7C78FB96E94DQ37576809-EA47AC88-CA22-4851-B3C6-AC865FF6031D
P2860
Risk stratification for progressive multifocal leukoencephalopathy in patients treated with natalizumab.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Risk stratification for progre ...... ents treated with natalizumab.
@en
Risk stratification for progre ...... ents treated with natalizumab.
@nl
type
label
Risk stratification for progre ...... ents treated with natalizumab.
@en
Risk stratification for progre ...... ents treated with natalizumab.
@nl
prefLabel
Risk stratification for progre ...... ents treated with natalizumab.
@en
Risk stratification for progre ...... ents treated with natalizumab.
@nl
P2093
P2860
P50
P356
P1476
Risk stratification for progre ...... ents treated with natalizumab.
@en
P2093
Gilles Edan
Tomas Olsson
Xavier Montalban
P2860
P304
P356
10.1177/1352458511435105
P577
2012-02-01T00:00:00Z